AUSTRALIA'S largest complementary medicines company Blackmores has reported first half F19 revenue record of $319 million, up 11%, despite China sales dropping 11% in the same period (PD breaking news yesterday).
Even so the company estimated that with China-influenced sales through Australian retailers included, sales to Chinese consumers were up around 8% in total for the half year.
The company also reported strong growth across other Asian markets: Korea +67%, Taiwan +150%, Hong Kong +39%, Indonesia +72% and other Asian segment revenue up 34% pcp to $53 million.
Blackmores' Bioceuticals brand leads the practitioner-only category with revenue up 7%.
Overall net profit for the half year was $34 million with EBIT profit up 268% in other Asian businesses.
The above article was sent to subscribers in Pharmacy Daily's issue from 20 Feb 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 20 Feb 19
